Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Madrigal Pharmaceuticals, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL).
On November 3, 2026, Madrigal disclosed in its quarterly report that its former Senior Vice President and Head of Clinical Development, Dr. Michael Charlton, had filed a whistleblower complaint against the Company. According to the complaint, Dr. Charlton repeatedly reported concerns that Madrigal was suppressing adverse liver-injury data, presenting efficacy results that could not be reconciled with source data, and allowing an unblinded board member and major shareholder to control the adjudication of clinical outcomes. Following this news, Madrigal’s stock price dropped.
What Potential Securities Violations Is BG&G Investigating?
- Whether Madrigal Pharmaceuticals, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether Madrigal Pharmaceuticals, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Should Madrigal Pharmaceuticals, Inc. (MDGL) Investors Do?
How Is Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Stock Trading Today?
Interactive chart showing the weekly share price history of NASDAQ:MDGL (NASDAQ:MDGL).
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”